NovaVax vaccine is excellent in safety and efficacy… Easy distribution and storage
SK Bioscience’s domestic factory produces all parts… Scheduled to start supply in the second quarter
3 million Pfizers also introduced… Scheduled to start inoculation in April
viewer
The government has secured an additional 23 million vaccines for the novel coronavirus infection (Corona 19), and a total of 79 million vaccines will be introduced in Korea. It has secured nearly twice the volume of 43.5 million people, the target of the number of vaccinations, excluding those under the age of 18 and pregnant women.
On the 16th, the Korea Centers for Disease Control and Prevention announced that it has confirmed the introduction of 20 million NovaVax vaccines and 3 million Pfizer vaccines. As a result, the government secured vaccines for a total of 79 million, including 10 million Kovacs, 10 million AstraZeneca, 20 million Modena, 6 million Janssen, 13 million Pfizer, and 20 million NovaVax, which are international vaccine purchasing projects. It’s justification. The number of vaccinations this year, which the government targets, is 1.81 times of 43.5 million people.
NovaVax vaccine, which accounts for about 25% of the total vaccine, is expected to provide a stable supply and demand because the entire amount is produced at SK Bioscience’s domestic plant. The government is planning to sequentially receive NovaVax vaccine from SK Bioscience from the second quarter. SK Bioscience completed the introduction of Corona 19 vaccine technology after signing a contract for development and production (CDMO) with NovaVax in August last year. Yang Dong-gyo’s vaccination and response promotion team’s Resource Management Team headed at a regular briefing on the day, saying, “Not only is Korea receiving domestically-produced vaccines, but SK Bioscience has the authority to supply and produce the vaccines more stably. “
NovaVax vaccine is known as a vaccine capable of catching three rabbits with safety, efficacy, and ease of storage and distribution.
The NovaVax vaccine secured by the government is expected to contribute to the goal of forming population immunity in November as it is excellent in terms of safety, preventive effect, and distribution and storage. This vaccine was developed as a synthetic antigen method that induces an immune response by synthesizing an antigenic protein, mixing it with an immune enhancing agent, and administering it to the human body. This method is a technology used in existing influenza and hepatitis B vaccines, and its safety is evaluated as being proven. According to NovaVax, a phase 3 clinical trial conducted in the UK last month showed an average of 89.3% of prevention effects. Compared to Modena (94.1%) and Pfizer (95%), this level is not too short. In addition, it can be stored and distributed at 2~8 degrees, and the shelf life is relatively long, 2~3 years, so it is easy to inoculate. Jeong Jae-hoon, a professor of preventive medicine at Gachon Gil Hospital, said, “Since the synthetic antigen platform used by NovaVax is a platform that has been widely used, there is no safety problem.” Kim Woo-joo Korea University Guro
viewer
viewer
“In terms of efficacy, safety, convenience, cost, and whether it is possible to mass-produce, it is inferior to the mRNA vaccine, but I think the quality is better than AstraZeneca,” said a professor of infectious medicine at the hospital. Eun-mi Chun, a professor of infectious medicine at Ewha Womans University Mokdong Hospital, said, “Because the NovaVax vaccine can be vaccinated just like a regular flu vaccine, you can visit nursing hospitals and nursing facilities in person.”
However, it is also evaluated that the mutant virus lacks NovaVax vaccine compared to the mRNA-based Pfizer/Moder vaccine. The NovaVax vaccine was 85.6% and 60% effective against mutant viruses in Britain and South Africa, respectively.
It is noteworthy whether the NovaVax vaccine will be vaccinated to elderly people aged 65 years or older who are excluded from the priority vaccination of the AstraZeneca vaccine. This is because it is easy to inoculate directly to a nursing hospital. The authorities plan to determine who will be vaccinated during the permit review process. “If it is judged that vaccination is difficult (over 65 years of age for the AstraZeneca vaccine), we are also considering using other vaccines such as Pfizer vaccine or Modena and Janssen vaccine that will come after March,” said Kyung-sil Chung, head of the vaccination management team. said.
Meanwhile, the starting point of the Pfizer vaccine has been advanced to April. The government signed an early supply negotiation with Pfizer to supply 500,000 people by the end of March and 3 million people in the second quarter. Yang said, “The timing of the supply is specified in the contract, so we expect the supply to be delivered without a hitch.”
/ Reporter Kim Seong-tae [email protected], Reporter Seo Ji-hye [email protected]
< 저작권자 ⓒ 서울경제, 무단 전재 및 재배포 금지 >